$1.72 Billion is the total value of Sofinnova Investments, Inc.'s 61 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 59.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMRN | Sell | Biomarin Pharmaceutical Inc | $24,986,000 | -0.0% | 294,750 | -2.3% | 1.45% | -30.1% |
| IRTC | Sell | iRhythm Technologies Inc | $17,551,000 | +14.3% | 140,095 | -1.4% | 1.02% | -20.1% |
| CYTK | Sell | Cytokinetics Inc | $15,539,000 | +23.3% | 320,722 | -0.0% | 0.90% | -13.9% |
| RXDX | Sell | Prometheus Biosciences Inc | $8,248,000 | -24.4% | 139,774 | -63.8% | 0.48% | -47.1% |
| ACET | Sell | Adicet Bio Inc | $6,996,000 | -7.6% | 491,965 | -5.1% | 0.41% | -35.4% |
| RGNX | Sell | Regenxbio Inc | $5,655,000 | -70.5% | 213,959 | -72.5% | 0.33% | -79.4% |
| IMTX | Sell | Immatics NV | $5,325,000 | -52.8% | 532,516 | -58.9% | 0.31% | -67.0% |
| GERN | Sell | Geron Corp | $2,783,000 | -35.7% | 1,189,208 | -57.4% | 0.16% | -55.0% |
| IMGN | Sell | ImmunoGen Inc | $2,401,000 | -53.2% | 502,393 | -56.0% | 0.14% | -67.3% |
| PTGX | Exit | Protagonist Therapeutics Inccall | $0 | – | -100,000 | -100.0% | -0.07% | – |
| CLDX | Exit | Celldex Therapeutics Inc | $0 | – | -48,304 | -100.0% | -0.11% | – |
| JNCE | Exit | Jounce Therapeutics Inc | $0 | – | -981,928 | -100.0% | -0.25% | – |
| Exit | Amylyx Pharmaceuticals Inc | $0 | – | -187,381 | -100.0% | -0.30% | – | |
| XNCR | Exit | Xencor Inc | $0 | – | -158,164 | -100.0% | -0.36% | – |
| SGEN | Exit | Seagen Inc | $0 | – | -27,894 | -100.0% | -0.41% | – |
| ARGX | Exit | argenx SEsponsored adr | $0 | – | -15,000 | -100.0% | -0.47% | – |
| CCXI | Exit | ChemoCentryx Inccall | $0 | – | -250,000 | -100.0% | -0.52% | – |
| HZNP | Exit | Horizon Therapeutics PLC | $0 | – | -100,297 | -100.0% | -0.67% | – |
| CCXI | Exit | ChemoCentryx Inc | $0 | – | -636,659 | -100.0% | -1.31% | – |
| VRTX | Exit | Vertex Pharmaceuticals Inc | $0 | – | -74,758 | -100.0% | -1.75% | – |
| XBI | Exit | SPDR S&P Biotech ETFput | $0 | – | -400,000 | -100.0% | -2.47% | – |
| NVO | Exit | Novo-Nordisk A Sadr | $0 | – | -273,873 | -100.0% | -2.54% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-08
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.